AU2023219770A1 - Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders - Google Patents
Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders Download PDFInfo
- Publication number
- AU2023219770A1 AU2023219770A1 AU2023219770A AU2023219770A AU2023219770A1 AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1 AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A AU2023219770 A AU 2023219770A AU 2023219770 A1 AU2023219770 A1 AU 2023219770A1
- Authority
- AU
- Australia
- Prior art keywords
- csf
- patient
- activity
- expression
- neurodegenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309220P | 2022-02-11 | 2022-02-11 | |
| US63/309,220 | 2022-02-11 | ||
| PCT/US2023/062374 WO2023154855A2 (en) | 2022-02-11 | 2023-02-10 | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023219770A1 true AU2023219770A1 (en) | 2024-08-22 |
Family
ID=87565120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023219770A Pending AU2023219770A1 (en) | 2022-02-11 | 2023-02-10 | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134959A1 (enExample) |
| EP (1) | EP4475874A4 (enExample) |
| JP (1) | JP2025508308A (enExample) |
| KR (1) | KR20240147980A (enExample) |
| CN (1) | CN118660715A (enExample) |
| AU (1) | AU2023219770A1 (enExample) |
| CA (1) | CA3242855A1 (enExample) |
| WO (1) | WO2023154855A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235795A2 (en) * | 2022-06-01 | 2023-12-07 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders |
| WO2025168003A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海市第四人民医院 | 一种治疗神经退行性疾病的药物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2017185085A1 (en) * | 2016-04-22 | 2017-10-26 | Board Of Regents Of The University Of Nebraska | Biomarkers for monitoring immune transformation |
| EP4103618A4 (en) * | 2020-02-12 | 2024-05-01 | The Scripps Research Institute | LONG-ACTING GM-CSF AND METHODS OF USE |
-
2023
- 2023-02-10 CA CA3242855A patent/CA3242855A1/en active Pending
- 2023-02-10 EP EP23753693.3A patent/EP4475874A4/en active Pending
- 2023-02-10 CN CN202380021043.5A patent/CN118660715A/zh active Pending
- 2023-02-10 JP JP2024542110A patent/JP2025508308A/ja active Pending
- 2023-02-10 WO PCT/US2023/062374 patent/WO2023154855A2/en not_active Ceased
- 2023-02-10 KR KR1020247024332A patent/KR20240147980A/ko active Pending
- 2023-02-10 AU AU2023219770A patent/AU2023219770A1/en active Pending
- 2023-02-10 US US18/837,235 patent/US20250134959A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242855A1 (en) | 2023-08-17 |
| WO2023154855A2 (en) | 2023-08-17 |
| CN118660715A (zh) | 2024-09-17 |
| US20250134959A1 (en) | 2025-05-01 |
| EP4475874A4 (en) | 2026-05-13 |
| JP2025508308A (ja) | 2025-03-26 |
| KR20240147980A (ko) | 2024-10-10 |
| EP4475874A2 (en) | 2024-12-18 |
| WO2023154855A3 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3583125B1 (en) | Albumin binding domain fusion proteins | |
| Harari et al. | Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis | |
| KR100439289B1 (ko) | 인터로이킨-18수용체단백질 | |
| US10695404B2 (en) | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs | |
| US20250134959A1 (en) | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders | |
| AU623698B2 (en) | Macrophage-derived inflammatory mediator (mip-2) | |
| JP2020517740A (ja) | 神経変性疾患を治療するためのcd14アンタゴニスト抗体 | |
| JP7678802B2 (ja) | Siglec-9ECD融合分子及びその使用方法 | |
| ITRM940794A1 (it) | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 | |
| CA2743394C (en) | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| WO2021063350A1 (zh) | 一种融合蛋白及其应用 | |
| CN120897934A (zh) | 抗pd-1/il-2融合蛋白、药物组合物和治疗应用 | |
| CN121002060A (zh) | 犬il-13的犬抗体 | |
| US20070149439A1 (en) | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo | |
| EP3917958A1 (en) | Treatment of neurotoxicity and / or cytokine release syndrome | |
| CN119013033A (zh) | 白细胞介素-2突变蛋白、融合蛋白、药物组合物以及治疗应用 | |
| US20240361339A1 (en) | Biomarkers for parkinson's disease | |
| CN118043672A (zh) | 帕金森病的生物标志物 | |
| WO2023235795A2 (en) | Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders | |
| US20240182535A1 (en) | Granulocyte macrophage-colony stimulating factor mutants | |
| HK40126456A (en) | Albumin binding domain fusion proteins | |
| HK40015886B (en) | Albumin binding domain fusion proteins | |
| HK40015886A (en) | Albumin binding domain fusion proteins | |
| JP2024542999A (ja) | インターロイキン-34を標的とする化合物及び方法 |